Correction: Obicetrapib for Heterozygous Familial Hypercholesterolemia (BROOKLYN Trial)

On April 17, 2026, Nature Medicine published an author correction to a landmark randomized clinical trial evaluating obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH), a genetic disorder affecting approximately 1 in 250 individuals worldwide and significantly elevating lifetime risk of premature atherosclerotic cardiovascular disease. The BROOKLYN trial, a Phase III, double-blind, placebo-controlled study, investigated the efficacy and safety of obicetrapib—a novel cholesteryl ester transfer protein (CETP) inhibitor—when added to maximally tolerated statin therapy in adults with HeFH who remained above LDL-cholesterol goals despite standard care. This correction clarifies minor statistical adjustments in the primary endpoint analysis without altering the trial’s overall conclusion: obicetrapib demonstrated a statistically significant and clinically meaningful reduction in LDL-C levels compared to placebo, reinforcing its potential role as a next-generation therapy for high-risk lipid disorders.

• Key Clinical Takeaways:
• Obicetrapib reduced LDL cholesterol by an additional 40% beyond statin monotherapy in HeFH patients, meeting the primary efficacy endpoint with a p-value <0.001 after correction.
• The drug exhibited a favorable safety profile, with no significant increase in adverse events leading to discontinuation compared to placebo, supporting its tolerability in long-term utilize.
• Funded by Esperion Therapeutics, the BROOKLYN trial provides robust Phase III evidence that may inform future LDL-lowering strategies for genetically driven hypercholesterolemia.

Understanding the Burden of Heterozygous Familial Hypercholesterolemia

Heterozygous familial hypercholesterolemia remains one of the most common and underdiagnosed inherited metabolic disorders, characterized by mutations in the LDLR, APOB, or PCSK9 genes that impair hepatic clearance of low-density lipoprotein cholesterol. Left untreated, HeFH accelerates atherosclerosis, leading to coronary artery disease in up to 50% of men and 30% of women by age 50. Despite widespread statin use, nearly 30% of HeFH patients fail to achieve LDL-C targets below 70 mg/dL, creating a critical therapeutic gap. The pathogenesis involves not only elevated LDL particle concentration but likewise increased arterial inflammation and endothelial dysfunction, necessitating therapies that move beyond conventional lipid-lowering approaches. Current guidelines from the American Heart Association and European Society of Cardiology emphasize aggressive LDL reduction, yet access to advanced therapies like PCSK9 inhibitors remains limited by cost and prior authorization hurdles.

Mechanism and Trial Design of Obicetrapib in the BROOKLYN Study

Obicetrapib functions as a selective CETP inhibitor, blocking the transfer of cholesteryl esters from high-density lipoprotein (HDL) to apoB-containing lipoproteins, thereby increasing HDL-C and reducing LDL-C and triglyceride levels. Unlike earlier CETP inhibitors that failed due to off-target effects on blood pressure or cortisol synthesis, obicetrapib demonstrates improved selectivity, minimizing adverse hormonal interactions. The BROOKLYN trial enrolled 1,206 adults with confirmed HeFH across 85 sites in North America and Europe, randomizing participants 1:1 to receive obicetrapib 10 mg daily or matching placebo, all while on background statin therapy (atorvastatin 40–80 mg or rosuvastatin 20–40 mg). The primary endpoint was percent change in LDL-C from baseline to week 12, with key secondary endpoints including changes in HDL-C, apolipoprotein B and high-sensitivity C-reactive protein (hs-CRP), a biomarker of vascular inflammation.

Efficacy, Safety, and Clinical Implications

At 12 weeks, obicetrapib reduced LDL-C by a mean of 40.1% compared to 2.3% in the placebo group (between-group difference: −37.8%; 95% CI, −40.2 to −35.4; p<0.001), a magnitude of effect comparable to adding a PCSK9 inhibitor to statin therapy. HDL-C increased by 95.7% with obicetrapib versus 3.1% with placebo, while apolipoprotein B decreased by 30.4%, reflecting a favorable shift in atherogenic particle burden. Importantly, hs-CRP decreased by 19.8%, suggesting potential anti-inflammatory benefits beyond lipid modification. Adverse events were balanced between groups, with nasopharyngitis and headache being the most common; no cases of hypertension, hepatic toxicity, or adrenal insufficiency were attributed to the study drug. Discontinuation due to adverse events occurred in 2.1% of the obicetrapib group versus 1.8% in placebo, indicating no significant safety signal.

“The BROOKLYN trial fills a critical evidence gap for CETP inhibition in genetically defined high-risk populations. Obicetrapib’s ability to dramatically lower LDL-C while improving HDL functionality positions it as a promising adjunct for patients who remain uncontrolled on statins alone.”

Funding, Transparency, and Regulatory Pathway

The BROOKLYN trial was fully funded by Esperion Therapeutics, the biopharmaceutical company developing obicetrapib under an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). Study design, data collection, and analysis were conducted in collaboration with academic research centers, with an independent data monitoring committee overseeing safety. All authors disclosed potential conflicts of interest, and the manuscript underwent rigorous peer review prior to publication. As of Q1 2026, Esperion has submitted a New Drug Application (NDA) to the FDA for obicetrapib in combination with statins for the treatment of HeFH and clinical atherosclerotic cardiovascular disease, with a potential approval decision expected in late 2026. The European Medicines Agency (EMA) is conducting a parallel review under its centralized procedure.

Connecting Patients to Advanced Lipid Management

For individuals with heterozygous familial hypercholesterolemia who struggle to reach LDL-C goals despite maximal statin therapy, timely access to emerging lipid-lowering agents is essential to reduce long-term morbidity and mortality. Patients requiring expert evaluation of genetic dyslipidemias and personalized treatment plans should consult with vetted lipid specialists who can assess eligibility for novel therapies like obicetrapib and coordinate comprehensive cardiovascular risk assessment. Similarly, clinics managing high-volume lipid disorder cases benefit from partnering with certified advanced diagnostic laboratories capable of performing lipoprotein subfraction analysis, Lp(a) testing, and genotyping for FH mutations—tools critical for precise diagnosis and monitoring therapeutic response.

“Genetic screening for FH remains vastly underutilized, yet identifying these patients early allows for aggressive intervention before irreversible vascular damage occurs. Therapies like obicetrapib represent a new frontier in precision lipidology.”

The publication of the BROOKLYN trial author correction underscores the importance of transparency in clinical research while affirming obicetrapib’s potential as a high-efficacy, well-tolerated option for LDL-C reduction in genetically susceptible populations. As the field moves toward combination therapies targeting multiple pathways in atherogenesis, agents that simultaneously lower LDL-C, raise functional HDL, and mitigate inflammation may redefine the standard of care for HeFH. Continued post-marketing surveillance and real-world evidence studies will be essential to assess long-term cardiovascular outcomes, adherence, and cost-effectiveness in diverse patient populations.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*